Weissert J, Ravvaz K. Cost-effectiveness of genomic-based warfarin therapy. Poster presented at: Aurora Scientific Day; May 25, 2016; Milwaukee, WI.
Poster presented at: Aurora Scientific Day; May 25, 2016; Milwaukee, WI.
Conclusions: Using patients' clinical and genetic information in warfarin therapy protocols can significantly reduce IS [ischemic stroke] and ICH [intracranial hemorrhage] related healthcare expenditures over a five-year period. The PG-protocol 3 generates the greatest total average savings at $78.98 per patient over five-years. The clinical and PG-protocols [pharmacogenomic-based protocols] only modestly reduce the absolute even rate for IS and ICH when compared to the current AHC 'Best-Practice' warfarin therapy protocol. However, with an average of 3,000 patients annually initiating warfarin for AF and the large acute care and five-year costs associated with IS and ICH, even incremental reductions in adverse events through PG-guided care produce savings. Given the substantial reduction in costs associated with genotyping patients, $78.98 per patient is likely an achievable price point at which using a PG-protocol would result in a neutral cost difference. Next steps include developing expense estimates to including PG-guidance into warfarin therapy work flow.